DGKA and cancer: Dominguez et al. reported that DGKα inhibition using R59022 and R59949, which are commercially available semi-DGKα-selective inhibitors (see Section 5.1), and silencing induced apoptosis of several cancer cell lines including brain glioblastoma and melanoma cells [8] (Figure 2).